Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01620255 · ClinicalTrials.gov registry record · Phase 2
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
- 20
- Study locations
NCT01620255 is a Phase 2 study of Ulcerative Colitis that has completed, run by Shire. The registered enrollment target is 357 participants, below the 2,054-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT01620255, a Phase 2 study of Ulcerative Colitis, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the dose or doses of PF-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-00547659 SC Injection
Study Locations (20)
California
- UCSD Health System-Pharmacy only - La Jolla
- Clinical and Translational Research Institute - La Jolla
- Perlman Medical Offices - La Jolla
- Thornton Hospital - La Jolla
- Community Clinical Trials - Orange
- GastroDiagnostics - Community Clinical Trials Drug - Orange
Connecticut
- Endoscopy Center of Connecticut, LLC - Guilford
- Endoscopy Center of Connecticut, LLC - Hamden
- Gastroenterology Center of Connecticut, PC - Hamden
- Medical REsearch Center of CT Drug - Hamden
- Medical Research Network of Connecticut - Hamden
Florida
- Florida Surgery Center - Altamonte Springs
- Gastroenterology Associates - Crystal River
- Research Consultant Group - Hialeah
- Th Palmetto Surgery Center - Hialeah
- Citrus Memorial Hospital - Inverness
Colorado
- Rocky Mountain Clinical Research, LLC. - Denver
- Clinical Research of the Rockies - Lafayette
- Rocky Mountain Gastroenterology Associates - Thornton
Arizona
- Mayo Clinic Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2016-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01620255
The ClinicalTrials.gov registry entry for NCT01620255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,054-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (83% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01620255 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT01620255 about?
NCT01620255 is a clinical study titled "A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis". To determine the dose or doses of PF-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.
What is the current status of trial NCT01620255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2012-11-02. Estimated completion is 2016-02-04.
What conditions does trial NCT01620255 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01620255?
The interventions under investigation include: Placebo (DRUG), PF-00547659 SC Injection (DRUG).
Who is sponsoring clinical trial NCT01620255?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01620255 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.